Daily Medication Pearl: Tralokinumab-ldrm (Adbry)
Tralokinumab-ldrm is a human immunoglobulin G4 monoclonal antibody indicated for the treatment of moderate-to-severe atopic dermatitis.
Medication Pearl of the Day: Tralokinumab-ldrm (Adbry)
Indication: Tralokinumab-ldrm (Adbry) is an interleukin-13 (IL-13) antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
- Dosing: The recommended dosage of Adbry is an initial dose of 600 mg (four 150 mg injections), followed by 300 mg (two 150 mg injections) administered every other week.
- Dosage forms: Injection 150 mg/mL solution in a single-dose prefilled syringe with needle guard.
- Adverse events: Most common adverse events (incidence ≥ 1%) are upper respiratory tract infections, conjunctivitis, injection site reactions, and eosinophilia.
- Mechanism of action: Tralokinumab-ldrm is a human immunoglobulin G4 monoclonal antibody that specifically binds to human IL-13 and inhibits its interaction with the IL-13 receptor α1 and α2 subunits.
- Manufacturer: LEO Pharma